blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3733185

EP3733185 - TREATING NON-SMALL CELL LUNG CANCER WITH ATR INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.10.2023
Database last updated on 11.04.2026
FormerThe patent has been granted
Status updated on  04.11.2022
FormerGrant of patent is intended
Status updated on  09.06.2022
FormerRequest for examination was made
Status updated on  05.02.2021
FormerThe application has been published
Status updated on  02.10.2020
Most recent event   Tooltip22.08.2025Lapse of the patent in a contracting state
New state(s): HU		published on 24.09.2025  [2025/39]
Applicant(s)For all designated states
Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210 / US
[2020/45]
Inventor(s)01 / POLLARD, John, Robert
Unit 88, Milton Park
Abingdon, Oxfordshire OX14 4RY / GB
02 / REAPER, Philip, Michael
Unit 88, Milton Park
Abingdon, OXfordshire OX14 4RY / GB
 [2020/45]
Representative(s)Tostmann, Holger Carl
Wallinger Ricker Schlotter Tostmann
Patent- und Rechtsanwälte Partnerschaft mbB
Zweibrückenstrasse 5-7
80331 München / DE
[2020/45]
Application number, filing date20180337.601.10.2012
[2020/45]
Priority number, dateUS201161542084P30.09.2011         Original published format: US 201161542084 P
[2020/45]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3733185
Date:04.11.2020
Language:EN
[2020/45]
Type: B1 Patent specification 
No.:EP3733185
Date:07.12.2022
Language:EN
[2022/49]
Search report(s)(Supplementary) European search report - dispatched on:EP05.10.2020
ClassificationIPC:A61K31/505, A61K31/506, A61P35/00, A61K31/4965, A61K31/497, A61K31/555, A61K31/7048, A61K31/7068, A61K33/24, A61N5/10, A61P1/18, A61P43/00
[2020/45]
CPC:
A61K31/497 (EP,US); A61K31/506 (RU); A61K31/4965 (EP,US);
A61K31/505 (RU); A61K31/555 (EP,US); A61K31/7048 (EP,US);
A61K31/7068 (EP,US); A61K33/243 (EP,RU,US); A61K45/06 (US);
A61P1/18 (EP); A61P35/00 (EP,US); A61P43/00 (EP);
A61K2121/00 (RU); A61N2005/1098 (EP,US) (-)
C-Set:
A61K31/4965, A61K2300/00 (US,EP);
A61K31/497, A61K2300/00 (US,EP);
A61K31/555, A61K2300/00 (EP,US);
A61K31/7048, A61K2300/00 (US,EP);
A61K31/7068, A61K2300/00 (EP,US);
A61K33/24, A61K2300/00 (EP,US)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/10]
Former [2020/45]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:BEHANDLUNG VON NICHTKLEINZELLIGEM LUNGENKREBS MIT ATR-HEMMERN[2020/45]
English:TREATING NON-SMALL CELL LUNG CANCER WITH ATR INHIBITORS[2020/45]
French:TRAITEMENT DU CANCER DU POUMON NON À PETITES CELLULES AVEC DES INHIBITEURS DE L'ATR[2020/45]
Examination procedure01.02.2021Amendment by applicant (claims and/or description)
01.02.2021Examination requested  [2021/10]
01.02.2021Date on which the examining division has become responsible
10.06.2022Communication of intention to grant the patent
14.10.2022Fee for grant paid
14.10.2022Fee for publishing/printing paid
14.10.2022Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP12772860.8  / EP2750679
Opposition(s)08.09.2023No opposition filed within time limit [2023/46]
Fees paidRenewal fee
16.06.2020Renewal fee patent year 03
16.06.2020Renewal fee patent year 04
16.06.2020Renewal fee patent year 05
16.06.2020Renewal fee patent year 06
16.06.2020Renewal fee patent year 07
16.06.2020Renewal fee patent year 08
16.06.2020Renewal fee patent year 09
27.10.2021Renewal fee patent year 10
27.10.2022Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY01.10.2012
HU01.10.2012
AL07.12.2022
AT07.12.2022
BG07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
MC07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SI07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
[2025/39]
Former [2025/36]CY01.10.2012
AL07.12.2022
AT07.12.2022
BG07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
MC07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SI07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2024/51]AL07.12.2022
AT07.12.2022
BG07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
MC07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SI07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2024/28]AL07.12.2022
AT07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
MC07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SI07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2023/51]AL07.12.2022
AT07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SI07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2023/46]AL07.12.2022
AT07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2023/39]AL07.12.2022
AT07.12.2022
CZ07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2023/38]AL07.12.2022
AT07.12.2022
CZ07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
PT10.04.2023
Former [2023/37]AL07.12.2022
AT07.12.2022
CZ07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
PT10.04.2023
Former [2023/35]AT07.12.2022
CZ07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
PT10.04.2023
Former [2023/34]EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RS07.12.2022
SE07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
PT10.04.2023
Former [2023/33]FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RS07.12.2022
SE07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
Former [2023/29]FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RS07.12.2022
SE07.12.2022
NO07.03.2023
GR08.03.2023
Former [2023/25]FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
PL07.12.2022
RS07.12.2022
SE07.12.2022
NO07.03.2023
GR08.03.2023
Former [2023/23]FI07.12.2022
LT07.12.2022
LV07.12.2022
SE07.12.2022
NO07.03.2023
GR08.03.2023
Former [2023/22]FI07.12.2022
LT07.12.2022
SE07.12.2022
NO07.03.2023
Former [2023/20]LT07.12.2022
NO07.03.2023
Documents cited:Search[I] WO2010071837  (VERTEX PHARMA et al.) [I] 1-8 * page 17; compounds IIA-7 * * paragraphs [0194] , [ 248] , [ 249] * * page 308; example 57A * * page 358; compounds IIA-7 * * claims 14, 172-178, 226-231 *
 [A] WO2010054398  (VERTEX PHARMA et al.) [A] 1-8 * the whole document *
 [AP] WO2011143425  (VERTEX PHARMA et al.) [AP] 1-8 * the whole document *
 [AP] WO2011143423  (VERTEX PHARMA et al.) [AP] 1-8 * the whole document *
 [A]   PHILIP M REAPER ET AL: "Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR", NATURE CHEMICAL BIOLOGY, vol. 7, no. 7, 13 April 2011 (2011-04-13), pages 428 - 430, XP055048149, ISSN: 1552-4450, DOI: 10.1038/nchembio.573 [A] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1038/nchembio.573
 [A]   PHILIP M REAPER ET AL: "Supplementary Information. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR", NATURE CHEMICAL BIOLOGY, vol. 7, no. 7, 13 April 2011 (2011-04-13), pages 1 - 26, XP055048405, ISSN: 1552-4450, DOI: 10.1038/nchembio.573 * the whole document *

DOI:   http://dx.doi.org/10.1038/nchembio.573
 [A]   JEAN-DAMIEN CHARRIER ET AL: "Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 7, 14 April 2011 (2011-04-14), pages 2320 - 2330, XP055008447, ISSN: 0022-2623, DOI: 10.1021/jm101488z [A] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm101488z
 [AP]   I M PIRES ET AL: "Targeting radiation-resistant hypoxic tumour cells through ATR inhibition", BRITISH JOURNAL OF CANCER, vol. 107, no. 2, 19 June 2012 (2012-06-19), pages 291 - 299, XP055048151, ISSN: 0007-0920, DOI: 10.1038/bjc.2012.265 [AP] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1038/bjc.2012.265
 [AP]   REMKO PREVO ET AL: "The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy", CANCER BIOLOGY & THERAPY, vol. 13, no. 11, 24 July 2012 (2012-07-24), US, pages 1072 - 1081, XP055531997, ISSN: 1538-4047, DOI: 10.4161/cbt.21093 [AP] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.4161/cbt.21093
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.